INSTITUT DE RECHERCHES SERVIER

Their core work

Institut de Recherches Servier is the research arm of the Servier pharmaceutical group, one of France's largest independent pharmaceutical companies. They conduct drug discovery and preclinical research across oncology, neurodegenerative diseases, and metabolic disorders. In H2020, they contributed proprietary compound libraries, screening capabilities, and disease models to large multi-partner initiatives — particularly IMI (Innovative Medicines Initiative) projects where pharma and academia collaborate on shared challenges. Their work spans from high-throughput screening and iPSC-based disease modeling to federated machine learning for drug discovery.

What they specialise in

How they've shifted over time

In the early period (2016–2017), Servier's research engagement centered on cancer biology, medicinal chemistry, and broad disease-area training networks — a classic large-pharma footprint in EU collaborative research. From 2018 onward, a clear shift emerged toward neurodegenerative diseases, stem cell technologies (iPSC biobanking), and computational approaches like federated machine learning for drug discovery. This evolution suggests Servier is actively building capabilities in precision medicine tools and privacy-preserving AI while maintaining its oncology base.

Servier is moving toward data-driven drug discovery and advanced cell models, signaling readiness for collaborations that combine AI/ML with disease biology — particularly in neurodegeneration.

How they like to work

Servier exclusively participates as a partner or third party — never as coordinator — which is typical for large pharma in IMI and RIA projects where they contribute proprietary assets (compound libraries, disease models, screening infrastructure) rather than leading project management. With 128 unique partners across 16 countries, they are well-connected across European pharma-academic consortia. Their consistent presence in large IMI-style projects (10+ partners) indicates comfort in big, multi-stakeholder collaborations where industry and academia share pre-competitive resources.

Servier has built a broad European network of 128 unique partners across 16 countries, heavily weighted toward large IMI-type consortia that bring together pharma companies, academic medical centers, and biotech SMEs. Their network footprint reflects deep integration into the European pharma-academic collaboration ecosystem.

What sets them apart

As a large, independent (non-publicly traded) French pharmaceutical company, Servier brings a combination rare in EU projects: significant pharma-grade infrastructure — compound libraries, screening platforms, preclinical models — without the bureaucratic constraints of publicly traded multinationals. Their participation in both traditional drug discovery consortia and frontier AI projects (MELLODDY) positions them as a pharma partner that bridges established wet-lab capabilities with emerging computational methods. For academic groups, partnering with Servier offers a direct pipeline into an organization with both the resources and the independence to move quickly on promising results.

Highlights from their portfolio

• MELLODDY
  Landmark project where 10 pharma companies used federated learning to collaboratively train drug discovery models without sharing proprietary chemical data — a first-of-its-kind approach.
• ITCC-P4
  Built a European pediatric cancer preclinical platform combining PDX, GEMM, and organoid models — directly addressing the critical gap in childhood cancer drug development.
• EBiSC2
  Established a sustainable European iPSC biobank providing standardized, disease-specific stem cell lines — key infrastructure for personalized medicine research across multiple disease areas.